HUTCHMED (China) Limited (HCM), a commercial-stage biopharmaceutical company, which delivered impressive financial results in 2023, has set its sights on further growth in China.
The company's marketed drugs in China include ELUNATE (fruquintinib) for the treatment of metastatic colorectal cancer, SULANDA (Surufatinib) for the treatment of pancreatic and non-pancreatic neuroendocrine tumors, and ORPATHYS (Savolitinib) indicated for lung cancer with MET gene alterations.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com